☆ 4.8 Correction

Caring for patients with cancer in the COVID-19 era (vol 26, pg 665, 2020)

NATURE MEDICINE (2020)

Get Full Text
Add to Collection

Journal

NATURE MEDICINE
Volume 26, Issue 7, Pages 1146-1146

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41591-020-0948-7

Keywords

-

Categories

Biochemistry & Molecular Biology Cell Biology Medicine, Research & Experimental

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

Alexander Drilon, Vivek Subbiah, Oliver Gautschi, Pascale Tomasini, Filippo de Braud, Benjamin J. Solomon, Daniel Shao-Weng Tan, Guzman Alonso, Juergen Wolf, Keunchil Park, Koichi Goto, Victoria Soldatenkova, Sylwia Szymczak, Scott S. Barker, Tarun Puri, Aimee Bence Lin, Herbert Loong, Benjamin Besse

Summary: In this study, selpercatinib demonstrated durable and robust responses in both previously treated and treatment-naive patients with RET fusion-positive NSCLC, including intracranial activity.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection
Article Oncology

Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison

Riccardo Lobefaro, Luigi Mariani, Giorgia Peverelli, Francesca Ligorio, Giovanni Fuca, Alessandro Rametta, Emma Zattarin, Rita Leporati, Daniele Presti, Beatrice Cantarelli, Catherine Depretto, Andrea Vingiani, Siranoush Manoukian, Gianfranco Scaperrotta, Giulia V. Bianchi, Giuseppe Capri, Giancarlo Pruneri, Filippo de Braud, Claudio Vernieri

Summary: Single-agent chemotherapy, alone or with immunotherapy, is the first-line standard-of-care treatment for advanced TNBC patients. This study supports the use of carboplatin-based doublets as first-line regimens and demonstrates better survival outcomes with carboplatin-gemcitabine in patients previously treated with taxanes. Further research is needed to investigate chemo-immunotherapy combinations containing carboplatin-based doublets.

CLINICAL BREAST CANCER (2023)

Add to Collection
Letter Oncology

Ascites During Selpercatinib Treatment: Need for a Multidisciplinary Approach

Leonardo Provenzano, Silvia Damian, Matteo Duca, Serena Della Valle, Filippo Guglielmo Maria de Braud

JOURNAL OF THORACIC ONCOLOGY (2023)

Add to Collection
Article Biochemical Research Methods

Development of nanomaterial enabling highly sensitive surface-assisted laser desorption/ionization mass spectrometry peptide analysis

Aline Cournut, Ioana Silvia Hosu, Flavie Braud, Paul Moustiez, Yannick Coffinier, Christine Enjalbal, Claudia Bich

Summary: This study developed a novel SALDI-MS approach based on steel plates, which were chemically modified and textured to achieve efficient peptide detection. Seven optimal steel plate surfaces were selected based on the criteria of D/I efficiency and deposit homogeneity, and compared with MALDI-MS analyses.

RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2023)

Add to Collection
Article Oncology

Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients

Margherita Rimini, Carles Fabregat-Franco, Mara Persano, Valentina Burgio, Francesca Bergamo, Monica Niger, Mario Scartozzi, Ilario Giovanni Rapposelli, Giuseppe Aprile, Francesca Ratti, Federica Pedica, Helena Verdaguer, Mario Rizzato, Federico Nichetti, Eleonora Lai, Alessandro Cappetta, Teresa Macarulla, Matteo Fassan, Filippo De Braud, Andrea Pretta, Francesca Simionato, Francesco De Cobelli, Luca Aldrighetti, Lorenzo Fornaro, Stefano Cascinu, Andrea Casadei-Gardini

Summary: This study investigated the prognostic impact of IDH1 mutations in patients with advanced iCCA after progression on first-line therapies. The presence of IDH1 mutations was associated with worse overall survival and worse objective response rate in second-line therapy. IDH1 mutations were confirmed as an independent negative prognostic factor.

TARGETED ONCOLOGY (2023)

Add to Collection
Article Oncology

A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)

Giuseppe Procopio, Melanie Claps, Chiara Pircher, Luca Porcu, Pierangela Sepe, Valentina Guadalupi, Ugo De Giorgi, Davide Bimbatti, Franco Nole, Francesco Carrozza, Sebastiano Buti, Roberto Iacovelli, Chiara Ciccarese, Cristina Masini, Cinzia Baldessari, Laura Doni, Antonio Cusmai, Angela Gernone, Sarah Scagliarini, Sandro Pignata, Filippo de Braud, Elena Verzoni

Summary: The study demonstrates that cabozantinib as second-line therapy after immune-checkpoint inhibitors is effective in mRCC patients and can prolong survival. Additionally, the safety profile of the drug can be managed.

TUMORI JOURNAL (2023)

Add to Collection
Article Immunology

Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters

Maria Rescigno, Chiara Agrati, Carlo Salvarani, Diana Giannarelli, Massimo Costantini, Alberto Mantovani, Raffaella Massafra, Pier Luigi Zinzani, Aldo Morrone, Stefania Notari, Giulia Matusali, Giuseppe Lauria Pinter, Antonio Uccelli, Gennaro Ciliberto, Fausto Baldanti, Franco Locatelli, Nicola Silvestris, Valentina Sinno, Elena Turola, Maria Teresa Lupo-Stanghellini, Giovanni Apolone

Summary: This study compared the B-cell, T-cell, and neutralizing antibody response to WT and Omicron BA.2 SARS-CoV-2 virus in patients with hematological malignancies, solid tumors, and immune-rheumatological diseases after the fourth dose of mRNA COVID-19 vaccine. The T-cell response was similarly boosted by the fourth dose across different subgroups, while the antibody response was improved only in patients not receiving B-cell targeted therapies. However, a small percentage of patients did not have neutralizing antibodies to either virus variants, making them vulnerable to SARS-CoV-2 infection. The increment of neutralizing antibodies was similar towards Omicron BA.2 and WT virus after the third or fourth dose of vaccine. Additional booster doses are recommended for frail patients to enhance the development of a B-cell response against Omicron and/or to enhance the T-cell response in patients treated with anti-CD20.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection
Article Oncology

A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer

David Pook, Daniel M. Geynisman, Joan Carles, Filippo de Braud, Anthony M. Joshua, Jose Luis Perez-Gracia, Casilda Llacer Perez, Sang Joon Shin, Bruno Fang, Minal Barve, Marco Maruzzo, Sergio Bracarda, Miso Kim, Yannick Kerloeguen, Jorge Daniel Gallo, Sophia L. Maund, Adam Harris, Kuan-Chieh Huang, Victor Poon, Dhruvitkumar S. Sutaria, Howard Gurney

Summary: The combination of ipatasertib and rucaparib showed manageable safety in patients with metastatic castration-resistant prostate cancer, but did not demonstrate synergistic or additive antitumor activity in previously treated patients.

CLINICAL CANCER RESEARCH (2023)

Add to Collection
Article Gastroenterology & Hepatology

Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers

Changhoon Yoo, Milind M. Javle, Helena Verdaguer Mata, Filippo de Braud, Jorg Trojan, Jean-Luc Raoul, Jin Won Kim, Makoto Ueno, Choong-kun Lee, Susumu Hijioka, Antonio Cubillo, Junji Furuse, Nilofer Azad, Masashi Sato, Yulia Vugmeyster, Andreas Machl, Marcis Bajars, John Bridgewater, Do-Youn Oh, Mitesh J. Borad

Summary: Bintrafusp alfa demonstrated clinical activity as second-line treatment for biliary tract cancers, showing durable responses and manageable safety.

HEPATOLOGY (2023)

Add to Collection
Article Oncology

Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study

Filippo de Braud, Christophe Dooms, Rebecca S. Heist, Celeste Lebbe, Martin Wermke, Anas Gazzah, Dirk Schadendorf, Piotr Rutkowski, Juergen Wolf, Paolo A. Ascierto, Ignacio Gil-Bazo, Shumei Kato, Maria Wolodarski, Meredith McKean, Eva Munoz Couselo, Martin Sebastian, Armando Santoro, Vesselina Cooke, Luca Manganelli, Kitty Wan, Anil Gaur, Jaeyeon Kim, Giordano Caponigro, Xuan-Mai Couillebault, Helen Evans, Catarina D. Campbell, Sumit Basu, Michele Moschetta, Adil Daud

Summary: This study explores a targeted therapy for treating NRAS-mutant melanoma, showing promising antitumor activity in patients with the use of LXH254 and trametinib in combination.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection
Article Oncology

A Phase Ib/II Study of WNT974+Encorafenib plus Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer

Josep Tabernero, Eric Van Cutsem, Elena Garralda, David Tai, Filippo De Braud, Ravit Geva, Mark T. J. van Bussel, Katia Fiorella Dotti, Elena Elez, Maria J. de Miguel, Kevin Litwiler, Danielle Murphy, Michelle Edwards, Van Karlyle Morris

Summary: This study evaluated the maximum tolerated dose of WNT974 in combination with encorafenib and cetuximab in patients with BRAF (V600E)-mutant metastatic colorectal cancer. The results showed a high incidence of adverse events and no evidence of improved anti-tumor activity, leading to study discontinuation.

ONCOLOGIST (2023)

Add to Collection
Article Oncology

Comprehensive transcriptomic analysis to identify biological and clinical differences in cholangiocarcinoma

Marco Silvestri, Trung Nghia Vu, Federico Nichetti, Monica Niger, Serena Di Cosimo, Filippo De Braud, Giancarlo Pruneri, Yudi Pawitan, Stefano Calza, Vera Cappelletti

Summary: This study aimed to provide a gene expression-based classification of extrahepatic and intrahepatic cholangiocarcinoma by collecting all available public records. Through unsupervised clustering analysis of gene expression data, four subgroups characterized by different immune infiltrate and signaling pathways were identified in both ICC and ECC. Class predictors were developed using short gene list signatures and subgroups of ICC tumors with different prognosis were identified in an independent dataset.

CANCER MEDICINE (2023)

Add to Collection
Article Oncology

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors

Emma Zattarin, Daniele Presti, Luigi Mariani, Caterina Sposetti, Rita Leporati, Alice Menichetti, Chiara Corti, Chiara Benvenuti, Giovanni Fuca, Riccardo Lobefaro, Francesca Ligorio, Leonardo Provenzano, Andrea Vingiani, Marta Del Vecchio, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra, Paola Zagami, Elisa Agostinetto, Flavia Jacobs, Pierluigi Di Mauro, Andrea Esposito, Carlo Alberto Giorgi, Luca Lalli, Laura Boldrini, Pier Paolo Berton Giacchetti, Ambra Carnevale Schianca, Valentina Guarneri, Rebecca Pedersini, Agnese Losurdo, Alberto Zambelli, Daniele Generali, Carmen Criscitiello, Giuseppe Curigliano, Giancarlo Pruneri, Filippo de Braud, Maria Vittoria Dieci, Claudio Vernieri

Summary: In 428 patients with HR+/HER2- advanced breast cancer, HER2-low status was found to be independently associated with worse progression-free survival (PFS) and overall survival (OS) compared to HER2-0 status. These findings suggest that HER2-low status could serve as a new prognostic biomarker in this clinical setting.

NPJ BREAST CANCER (2023)

Add to Collection
Article Oncology

The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis

Leonardo Provenzano, Riccardo Lobefaro, Francesca Ligorio, Emma Zattarin, Luca Zambelli, Caterina Sposetti, Daniele Presti, Giulia Montelatici, Angela Ficchi, Antonia Martinetti, Alessio Arata, Marta Del Vecchio, Claudia Lauria Pantano, Barbara Formisano, Giulia Valeria Bianchi, Giuseppe Capri, Filippo de Braud, Claudio Vernieri, Giovanni Fuca

Summary: The study aims to test the prognostic ability of a novel inflammatory biomarker, the pan-immune-inflammation value (PIV), based on complete blood count (CBC), in patients with advanced triple-negative breast cancer (aNBC) who received first-line platinum-based chemotherapy. The results showed that PIV could serve as a prognostic factor and is associated with the efficacy of chemotherapy.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2023)

Add to Collection
Article Oncology

Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC)

Stefano Cavalieri, Viviana Vitolo, Amelia Barcellini, Sara Ronchi, Angelica Facoetti, Chiara Campo, Catherine Klersy, Silvia Molinelli, Francesco Agustoni, Virginia Valeria Ferretti, Annalisa De Silvestri, Marco Platania, Michele Del Vecchio, Marco Durante, Alexander Helm, Claudia Fournier, Filippo de Braud, Paolo Pedrazzoli, Ester Orlandi, Lisa Licitra

Summary: ICONIC is a phase II clinical trial that aims to assess the feasibility and clinical activity of combining carbon ion radiotherapy with immune checkpoint inhibitors in cancer patients. This study will provide controlled data regarding the safety of this novel therapeutic combination, as no previous clinical trials have evaluated it.

FUTURE ONCOLOGY (2023)

Add to Collection
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.